Journal-based CME Course: Managing Adverse Effects of Incretin-Based Medications for Obesity

Activity ID

14125

Expires

July 29, 2028

Format Type

Journal-based

CME Credit

Fee

$30

CME Provider: JAMA

Description of CME Course

This JAMA Insights explores optimal strategies for managing the adverse effects associated with incretin-based medications for obesity, including semaglutide and tirzepatide.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

ABMS Member Board Approvals by Type

ABMS Lifelong Learning CME Activity

Allergy and Immunology

Anesthesiology

Colon and Rectal Surgery

Family Medicine

Medical Genetics and Genomics

Nuclear Medicine

Ophthalmology

Pathology

Physical Medicine and Rehabilitation

Plastic Surgery

Preventive Medicine

Psychiatry and Neurology

Radiology

Thoracic Surgery

Urology

More Information

Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

General Information on CME Activity

Educational Objectives

To identify the key insights or developments described in this article

Keywords

Obesity, Adverse Drug Events, Clinical Pharmacy and Pharmacology, Diabetes, Diabetes and Endocrinology

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jama.2025.11153